Arimoclomol
showed promise as a treatment for the most common type of inflammatory
myopathy in adults over age 50 in a 1-year, phase IIa,
"proof-of-concept" study.
Not only was the novel oral agent "well tolerated,"
which was the study's main objective to assess, but it also showed early
signs that it could be effective in the treatment of patients with
sporadic inclusion body myositis (IBM). Indeed, there was a trend toward slower deterioration in physical function and
muscle strength for arimoclomol when compared against placebo at 8 months'
follow-up.
Click here to view the full EULAR 2013 Congress report
Related News
Close
